**European Cancer Inequalities Registry** 

# Country Cancer Profile 2023

Mark Pearson, Deputy Director of Employment, Labour and Social Affairs, OECD












# The burden of cancer in Europe is devastating, and marked with strong inequalities

#### The overwhelming burden of cancer in the EU





## There were over 2.6 million of new cancer cases in 2020, equivalent to 1 EU citizen diagnosed with cancer every 12 seconds




Source: European Cancer Information System (ECIS). From <a href="https://ecis.jrc.ec.europa.eu">https://ecis.jrc.ec.europa.eu</a>, accessed on 09/05/2022. © European Union, 2022.

#### Cancer mortality rates have decreased over time





But cancer is still the second leading cause of mortality in 2019 following CVD




Source: Eurostat Database.

# Nordic countries are performing better with more gender equity





Within countries, cancer mortality rate is almost 75% higher among men than women across EU countries




Source: Eurostat Database.

# Interventions to reduce socio-economic inequalities in cancer mortality should focus on low-educated people





Age-standardised cancer mortality rates per 100 000 population by education



Source: Vaccarella, S. et al. (2022), "Socioeconomic inequalities in cancer mortality between and within countries in Europe: A population-based study", *The Lancet Regional Health Europe*, Vol. 100551, <a href="https://doi.org/10.1016/j.lanepe.2022.100551">https://doi.org/10.1016/j.lanepe.2022.100551</a>.






1. Improve prevention

## Smoking is one of the largest preventable risk factor for cancer





Smoking remains more common among low socio-economic status: smoking is 50% higher among low income than high income people in EU countries








2. Improve accessibility

# All EU countries have opportunities to improve access to early diagnoses





Self-reported participation to cervical cancer screening programmes varies nearly 3-fold across countries and almost 2-fold across education groups in the EU




Source: Eurostat database, EHIS.

## Access to oncology medicines remains unequal across EU countries





Denmark and Germany have the largest number of product/indications approved and covered



Number of sample product/indication pairs

Source: Chapman, Paris and Lopert (2020).






3. Improve quality

# Implementing evidence-based practice to promote quality of cancer care





While survival rates have increased in most EU countries, there is still room for improvement in care quality



Note: Data refer to people diagnosed between 2010 and 2014. Source: CONCORD programme, London School of Hygiene and Tropical Medicine.

#### Measurement is key to inform policy and practice





We only measure, regularly, about half of the data we need

Risk factors such as smoking and obesity
Incidence
Cancer screening
Stage distribution
Hospital utilisation (average length of stay, discharges)
Survival and mortality
Patient-reported outcomes
Resources (e.g. oncologists, radiologists)
Spending on cancer care
Access to cancer therapy (e.g. authorisation, coverage, waiting time, affordability of cancer drugs)






4. Improve resilience

# The COVID-19 pandemic had a major impact in disrupting cancer care







#### Decreases in uptake of cancer screening



Source: Österr. Brustkrebs-Früherkennungsprogramm (BKFP) / Gesundheit Österreich GmbH (GOeG).



#### Reduction in the notification of new malignant cases



#### Key findings





Prevention

Invest in health promotion and disease prevention policies to prevent cancer through comprehensive prevention policies

Accessibility

Invest in early diagnoses programmes to ensure timely access to cancer care and treatment, and in health workforce to increase recruitment and retention rates

Quality

To improve cancer quality and address inequalities in cancer care, countries need to collect and use data for monitoring and benchmarking performance

Resilience

Minimising any disruption in cancer screenings is key to prevent a backlog of undiagnosed cancer patients and improve survival probabilities

## Thank you

Mark.Pearson@oecd.org









